VTRS / Viatris to Report Second Quarter 2023 Financial Results on August 7, 2023

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses. more_horizontal

Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be eva more_horizontal

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat more_horizontal

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. more_horizontal

Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities an more_horizontal

VTRS lost its Humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the former similarly losing another growth prospects more_horizontal

Viatris is advancing in its plan to become leaner and pay off its debt. To do so, it's offloading a trio of non-core business segments. more_horizontal

Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Activ more_horizontal